nach oben

Journal of Inherited Metabolic Disease

Erschienen in:

01.07.2014 | ICIEM Symposium 2013

What is new for monoamine neurotransmitter disorders?

verfasst von: Clara Marecos, Joanne Ng, Manju A. Kurian

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The monoamine neurotransmitter disorders are increasingly recognized as an expanding group of inherited neurometabolic syndromes caused by disturbances in the synthesis, transport and metabolism of the biogenic amines, including the catecholamines (dopamine, norepinephrine, and epinephrine) and serotonin. Disturbances in monoamine metabolism lead to neurological syndromes that frequently mimic other conditions, such as hypoxic ischemic encephalopathy, cerebral palsy, parkinsonism-dystonia syndromes, primary genetic dystonia and paroxysmal disorders. As a consequence, neurotransmitter disorders are frequently misdiagnosed. Early and accurate diagnosis of these neurotransmitter disorders is important, as many are highly amenable to, and some even cured by, therapeutic intervention. In this review, we highlight recent advances in the field, particularly the recent extensive characterization of known neurotransmitter disorders and identification of novel neurotransmitter disorders. We also provide an overview of current and future research in the field focused on developing novel treatment strategies.

Allen GF, Land JM, Heales SJ (2009) A new perspective on the treatment of aromatic L-amino acid decarboxylase deficiency. Mol Genet Metab 97(1):6–14PubMedCrossRef

Blackstone C (2009) Infantile parkinsonism-dystonia: a dopamine “transportopathy”. J Clin Invest 119:1455–1458PubMedCentralPubMed

Blackstone C (2011) Infantile parkinsonism-dystonia due to dopamine transporter gene mutations: another genetic twist. Lancet Neurol 10(1):24–25PubMedCrossRef

Bonafé L, Thőny B, Penzien JM, Czarnecki B, Blau N (2001a) Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia. Am J Hum Genet 69:269–277PubMedCentralPubMedCrossRef

Bonafé L, Thöny B, Leimbacher W, Kierat L, Blau N (2001b) Diagnosis of dopa-responsive dystonia and other tetrahydrobiopterin disorders by the study of biopterin metabolism in fibroblasts. Clin Chem 47(3):477–485PubMed

Brasil S, Viecelli HM, Meili D et al (2011) Pseudoexom exclusion by antisense therapy in 6-Pyruvoyl –tetrahydrobiopterin synthase deficiency. Hum Mutat 32:1019–1027PubMedCrossRef

Brun L, Ngu LH, Keng WT (2010) Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology 75(1):64–71PubMedCrossRef

Cawello W, Kim SR, Braun M, Elshoff JP, Ikeda J, Funaki T (2013) Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. Clin Drug Investig. doi:10.1007/s40261-013-0150-5 PubMedCentral

Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27(3):275–280PubMedCentralPubMedCrossRef

Chang Y, Sharma R, Marsh J et al (2004) Levodopa-responsive aromatic L–amino acid decarboxylase deficiency. Ann Neurol 55(3):435–438PubMedCrossRef

Chi CS, Lee HF, Tsai CR (2012) Tyrosine hydroxylase deficiency in Taiwanese infants. Pediatr Neurol 46(2):77–82PubMedCrossRef

De Grandis E, Serrano M, Pérez-Dueñas B et al (2010) Cerebrospinal fluid alterations of the serotonin product, 5-hydroxyindolacetic acid, in neurological disorders. J Inherit Metab Dis 33(6):803–809PubMedCrossRef

Eberling JL, Jaqust WJ, Christine CW et al (2008) Results from phase 1 safety trial of hAADC gene therapy for Parkinson disease. Neurology 80:1980–1983CrossRef

Espay AJ, Chen R (2013) Myoclonus. Continuum (Minneap Minn) 19 (5 Movement Disorders):1264–86

Fernandez-Alvarez E (2009) Movement disorders in children: recent advances in management. Indian J Pediatr 76:531–536PubMedCrossRef

Friedman J, Hyland K, Blau N, MacCollin M (2006) Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin reductase deficiency. Neurology 67:2032–2035PubMedCrossRef

Friedman J, Roze E, Abdenau JE et al (2012) Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 71:520–530PubMedCrossRef

Garcia-Cazorla A, Duarte S, Serrano M et al (2008) Mitochondrial diseases mimicking neurotransmitter defects. Mitochondrion 8(3):273–278PubMedCrossRef

Giovanniello T, Leuzzi V, Carducci C et al (2007) Tyrosine hydroxylase deficiency presenting with a biphasic clinical course. Neuropediatrics 38(4):213–215PubMedCrossRef

Henriksen FH, Yasmeen S, Skjørringe T et al. (2012) Atypical dopamine transporter deficiency syndrome in two adult males with molecular characterisation of new transporter variants. New Orleans, LA: Soc Neurosci Meet Plann 2012, Poster 042

Hwu WL, Muramatsu S, Tseng SH et al (2012) Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med 4(134):134ra61PubMed

Hyland K, Surtess RAH, Rodeck C, Clayton PT (1992) Aromatic l-amino acid decarboxylase deficiency: clinical features, diagnosis and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 42:1980–1988PubMedCrossRef

Kurian MA (2013) What is the role of dopamine in childhood neurological disorders? Dev Med Child Neurol 55:490–496CrossRef

Kurian M, Gissen P, Smith M, Heales S, Clayton P (2011a) The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol 10:721–733PubMedCrossRef

Kurian MA, Li Y, Zhen J et al (2011b) Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol 10(1):54–62PubMedCrossRef

Kurian MA, Zhen J, Cheng SY et al (2009) Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. J Clin Invest 119(6):1595–1603PubMedCentralPubMed

Lee HF, Tsai CR, Chi CS, Chang TM, Lee HJ (2009) Aromatic L-amino acid decarboxylase deficiency in Taiwan. Eur J Paediatr Neurol 13(2):135–140PubMedCrossRef

Leuzzi V, Carducci C, Tolve M, Giannini MT, Angeloni A, Carducci C (2013) Very early pattern of movement disorders in sepiapterin reductase deficiency. Neurology 81(24):2141–2142PubMedCrossRef

Lohmann E, Koroglu Ç, Hanagasi H, Dursun B, Tasan E, Tolun A (2012) A homozygous frameshift mutation of sepiapterin reductase gene causing parkinsonism with onset in childhood. Parkinsonism Relat Disord 18(2):191–193PubMedCrossRef

Mastrangelo M, Caputi C, Galosi S, Giannini MT, Leuzzi V (2013) Transdermal rotigotine in the treatment of aromatic L-amino acid decarboxylase deficiency. Mov Disord 28(4):556–557PubMedCrossRef

Molero-Luis M, Serrano M, Ormazábal A et al (2013) Homovanillic acid in cerebrospinal fluid of 1388 children with neurological disorders. Dev Med Child Neurol 55(6):559–566PubMedCrossRef

Moran MM, Allen NM, Treacy EP, King MD (2011) “Stiff neonate” with mitochondrial DNA depletion and secondary neurotransmitter defects. Pediatr Neurol 45(6):403–405PubMedCrossRef

Neville BG, Parascandalo R, Farrugia R, Felice A (2005) Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain 128(10):2291–2296PubMedCrossRef

Ng J, Tuschl K, Kinali et al (2013) TH gene-negative infantile onset severe dopamine deficiency syndrome: a novel neurotransmitter disorder? Dev Med Child Neurol 5(S1):15

Ng J, Zhen J, Meyer E et al. (2014) Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain. doi:10.1093/brain/awu022

Pons R, Ford B, Chiriboga CA et al (2004) Aromatic amino acid decarboxylase deficiency: clinical features, treatment, prognosis. Neurology 62:1058–1065PubMedCrossRef

Pons R, Syrengelas D, Youroukos S et al (2013) Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Mov Disord 28(8):1058–1063PubMedCrossRef

Rilstone J, Alkhater R, Minassian B (2013) Brain dopamine–serotonin vesicular transport disease and its treatment. N Engl J Med 368:543–550PubMedCrossRef

Stamelou M, Mencacci NE, Cordivari C et al (2012) Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology 79(5):435–441PubMedCentralPubMedCrossRef

Swoboda K, Furukawa Y (2008) Tyrosine hydroxylase deficiency. GeneReviewsTM. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK1437/ in December 2013

Tay SK, Poh KS, Hyland K et al (2007) Unusually mild phenotype of AADC deficiency in 2 siblings. Mol Genet Metab 91(4):374–378PubMedCrossRef

Tormenti MJ, Tomycz ND, Coffman KA, Kondziolka D, Crammond DJ, Tyler-Kabara EC (2011) Bilateral subthalamic nucleus deep brain stimulation for dopa-responsive dystonia in a 6-year-old child. J Neurosurg Pediatr 7(6):650–653PubMedCrossRef

Verbeek MM, Willemsen MA, Wevers RA et al (2008) Two Greek siblings with sepiapterin reductase deficiency. Mol Genet Metab 94(4):403–409PubMedCrossRef

Willemsen MA, Verbeek MM, Kamsteeg EJ et al (2010) Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 133(6):1810–1822PubMedCrossRef

Yeung WL, Wong VC, Chan KY et al (2011) Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency. J Child Neurol 26(2):179–187PubMedCrossRef

Zorzi G, Redweik U, Trippe H, Penzien JM, Thöny B, Blau N (2002) Detection of sepiapterin in CSF of patients with sepiapterin reductase deficiency. Mol Genet Metab 75:174–177PubMedCrossRef

Titel: What is new for monoamine neurotransmitter disorders?
verfasst von: Clara Marecos
Joanne Ng
Manju A. Kurian
Publikationsdatum: 01.07.2014
Verlag: Springer Netherlands
Erschienen in: Journal of Inherited Metabolic Disease / Ausgabe 4/2014
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-014-9697-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

What is new for monoamine neurotransmitter disorders?

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Krebspatienten impfen: Was? Wen? Und wann nicht?

Nierenultraschall: Tipps vom Profi

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

„KI sieht, was wir nicht sehen“

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

The potential of exosomes in diagnosis and treatment of inborn errors of metabolism

Mitochondrial transporters of the SLC25 family and associated diseases: a review

A brief overview of galactosemia newborn screening in the United States

Treatment of lysosomal storage disorders: successes and challenges

Parkinsonism and inborn errors of metabolism

Modelling inborn errors of metabolism in zebrafish

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Krebspatienten impfen: Was? Wen? Und wann nicht?

Nierenultraschall: Tipps vom Profi

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

„KI sieht, was wir nicht sehen“

Update Innere Medizin